European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis

The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish f...

Full description

Saved in:
Bibliographic Details
Published inJournal of the European Academy of Dermatology and Venereology Vol. 31; no. 10; pp. 1581 - 1594
Main Authors Knobler, R., Moinzadeh, P., Hunzelmann, N., Kreuter, A., Cozzio, A., Mouthon, L., Cutolo, M., Rongioletti, F., Denton, C.P., Rudnicka, L., Frasin, L.A., Smith, V., Gabrielli, A., Aberer, E., Bagot, M., Bali, G., Bouaziz, J., Braae Olesen, A., Foeldvari, I., Frances, C., Jalili, A., Just, U., Kähäri, V., Kárpáti, S., Kofoed, K., Krasowska, D., Olszewska, M., Orteu, C., Panelius, J., Parodi, A., Petit, A., Quaglino, P., Ranki, A., Sanchez Schmidt, J.M., Seneschal, J., Skrok, A., Sticherling, M., Sunderkötter, C., Taieb, A., Tanew, A., Wolf, P., Worm, M., Wutte, N.J., Krieg, T.
Format Journal Article
LanguageEnglish
Published England 01.10.2017
Subjects
Diagnosis, Differential
Humans
Nephrogenic Fibrosing Dermopathy - diagnosis
Nephrogenic Fibrosing Dermopathy - pathology
Nephrogenic Fibrosing Dermopathy - therapy
Scleredema Adultorum - diagnosis
Scleredema Adultorum - pathology
Scleredema Adultorum - therapy
Scleromyxedema - diagnosis
Scleromyxedema - pathology
Scleromyxedema - therapy
Online AccessGet full text
ISSN0926-9959
1468-3083
1468-3083
DOI10.1111/jdv.14466

Cover

More Information
Summary:The term ‘sclerosing diseases of the skin’ comprises specific dermatological entities which have fibrotic changes of the skin in common. These diseases mostly manifest in different clinical subtypes according to cutaneous and extracutaneous involvement and can sometimes be difficult to distinguish from each other. The present guideline focuses on characteristic clinical and histopathological features, diagnostic scores and the serum autoantibodies most useful for differential diagnosis. In addition, current strategies in the first‐ and advanced‐line therapy of sclerosing skin diseases are addressed in detail. Part 2 of this guideline provides clinicians with an overview of the diagnosis and treatment of scleromyxedema, scleredema (of Buschke) and nephrogenic systemic sclerosis (nephrogenic fibrosing dermopathy).
Bibliography:Prof. Dr. Maurizio Cutolo received research grants from Actelion, Bristol‐Myers Squibb, Horizon and Mundipharma.
Prof. Dr. Lidia Rudnicka is consultant for diverse Polish governmental institutions from which she also received research grants.
Prof. Dr. Michael Sticherling received research grants from Novartis; consultancy fees from AbbVie, Actelion Amgen, Celgene, Janssen‐Cilag, Leo Pharma, Lilly, Pfizer, Merck Sharp & Dohme, Mundipharma, and Novartis; payment for lectures from AbbVie, Actelion Celgene, Janssen‐Cilag, Leo Pharma, Pfizer, Merck Sharp & Dohme, Novartis, and Dermapharm; payment for manuscript preparation from Janssen‐Cilag; and royalties from Becton‐Dickinson. Prof.
Dr. Thomas Krieg received research grants and payment for participation in review activities as well as for lectures from Actelion. All other authors have no potential conflicts of interests to declare.
Dr. Ivan Foeldvari received consulting honoraria from AbbVie, Chugai Pharma, Bayer, Roche/Genentech and Novartis, and support for travel to meetings from Novartis, Bayer and AbbVie.
Prof. Dr. Vanessa Smith received research grants from Actelion, Boehringer Ingelheim, Roche/Genentech, Galapagos NV and Merck Sharp & Dohme.
Prof. Dr. Kristian Kofoed has board membership with Janssen‐Cilag, AbbVie, Celgene, Novartis, Sanofi Pasteur, Merck Sharp & Dohme and Leo Pharma; received research grants from Novartis, Sanofi Pasteur and Merck Sharp & Dohme; speakers fees from Pfizer, Janssen‐Cilag, AbbVie, Meda, Eli Lilly, Sanofi Pasteur, Merck Sharp & Dohme, Gilead, and Leo Pharma; payment for manuscript preparation and development of educational presentations from Sanofi Pasteur and Merck Sharp & Dohme; and support for travel to meetings from Eli Lilly, Pfizer, AbbVie and Janssen‐Cilag.
Prof. Dr. Robert Knobler received consultancy fees from Therakos/Mallinckrodt and Actelion.
Dr. Antoine Petit received consultancy fees from Roche, Shire Human Genetic Therapies and HRA Pharma; payment for manuscript preparation from Janssen, Glaxo Smith Kline, Pfizer, and Merck Sharp & Dohme; and support for travel to meetings from Janssen‐Cilag, Novartis, Glaxo Smith Kline, Merck Sharp & Dohme, Abbott and Pfizer.
Prof. Dr. Camille Frances received payment for lectures form Actelion and Novartis.
Prof. Dr. Margitta Worm received consultancy fees and support for travel to meetings from Actelion. Prof.
Funding Sources
Prof. Dr. Nicolas Hunzelmann received lecture fees from Actelion, Bayer, and Roche.
Dr. Pia Moinzadeh received a research grant, consulting honoraria and fees for lectures and participation in review activities from Actelion. Prof.
Prof. Dr. Armando Gabrielli received support for travel to meetings from Roche, AbbVie, Actelion and Pfizer.
Dr. Malgorzata Olszewska received grants from Polish governmental institutions.
Prof. Dr. Christopher Denton received research grants from Actelion, Roche and CSL Behring, and consulting fees from Actelion, Glaxo Smith Kline, Bayer and Roche.
Dr. Alexander Kreuter received fees for lectures and manuscript preparation from Actelion, and had advisory board membership with Sanofi Pasteur, Merck Sharp & Dohme, and AbbVie.
Prof. Dr. Luc Mouthon has board membership with Actelion, received a research grant from CSL Behring, and payment for lectures and for development of educational presentations from Actelion, Roche and LFB Biomedicaments.
Dr. Cord Sunderkötter received research grants from Actelion, Novartis, Boehringer Ingelheim, Roche/Genentech, Galderma, Pfizer and Bristol‐Myers Squibb.
Dr. Ulrike Just received support for travel to meetings from Therakos/Mallinckrodt.
Prof. Dr. Elisabeth Aberer received support for travel to meetings from Glaxo Smith Kline, Allmiral, Bayer and Ratiopharm.
Prof. Dr. Aurora Parodi has board membership with Galderma, Novartis, AbbVie and Pfizer; received payment for expert testimony from Pfizer, Novartis, Janssen Cilag and AbbVie; research grants from Pfizer; speakers’ fees from UCB Pharma and Novartis; and payment for manuscript preparation from Almirall and Galderma.
Conflicts of interests
Prof. Dr. Sarolta Kárpáti received consultancy fees from Janssen‐Cilag and AbbVie, and a research grant from Bristol‐Myers Squibb and has relationships with Roche, Novartis and Amgen.
Dr. Catherine Orteu is consultant for Shire Human Genetic Therapies from where she also received speakers’ fees, and received grants form Dermatrust, Royal Free NHS Foundation Trust and Rosetrees Trust.
Prof. Dr. Martine Bagot received support for travel to meetings from Pfizer, Janssen‐Cilag, and Novartis for travel to scientific meetings.
Prof. Dr. Ahmad Jalili received consultancy fees from Eli Lilly, Leo Pharma and Novartis, and payment for lectures from Eli Lilly, Leo Pharma, Novartis, Janssen‐Cilag and AbbVie.
Prof. Dr. Peter Wolf received consultancy fees and support for travel to meetings from Therakos/Mallincrodt.
Prof. Dr. Jean‐David Bouaziz has board membership with Novartis, Lilly and Neovacs, received grants from Therakos/Mallinckrodt, and support for travel to meetings from AbbVie.
None declared.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
content type line 23
ISSN:0926-9959
1468-3083
1468-3083
DOI:10.1111/jdv.14466